SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of ...
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE)-- BioAtla, Inc. (NASDAQ: BCAB or the "Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ...
BioAtla (BCAB) has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share ...
SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally ...
SAN DIEGO, CA – December 8, 2015 – BioAtla® LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered ...
BioAtla (NASDAQ:BCAB) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints for the OSV registrational study in second-line plus oropharyngeal squamous cell carcinoma ...
BioAtla’s CAB platform offers increased potency and safety, positioning it favorably for growth. The company expects non-dilutive financing through partnerships, with cash sufficient to fund ...
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results